Shattuck Labs (STTK) Competitors $0.81 +0.06 (+8.62%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.80 -0.01 (-1.14%) As of 07/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock STTK vs. IPHA, LFVN, IMRX, ENTA, SPRO, LXEO, THTX, GLSI, RAPT, and IKTShould you be buying Shattuck Labs stock or one of its competitors? The main competitors of Shattuck Labs include Innate Pharma (IPHA), Lifevantage (LFVN), Immuneering (IMRX), Enanta Pharmaceuticals (ENTA), Spero Therapeutics (SPRO), Lexeo Therapeutics (LXEO), Theratechnologies (THTX), Greenwich LifeSciences (GLSI), Rapt Therapeutics (RAPT), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. Shattuck Labs vs. Its Competitors Innate Pharma Lifevantage Immuneering Enanta Pharmaceuticals Spero Therapeutics Lexeo Therapeutics Theratechnologies Greenwich LifeSciences Rapt Therapeutics Inhibikase Therapeutics Shattuck Labs (NASDAQ:STTK) and Innate Pharma (NASDAQ:IPHA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations. Does the media refer more to STTK or IPHA? In the previous week, Shattuck Labs had 1 more articles in the media than Innate Pharma. MarketBeat recorded 2 mentions for Shattuck Labs and 1 mentions for Innate Pharma. Shattuck Labs' average media sentiment score of 0.77 beat Innate Pharma's score of 0.00 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innate Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in STTK or IPHA? 58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 12.0% of Shattuck Labs shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend STTK or IPHA? Shattuck Labs presently has a consensus price target of $7.50, indicating a potential upside of 826.84%. Innate Pharma has a consensus price target of $11.00, indicating a potential upside of 472.92%. Given Shattuck Labs' higher possible upside, equities research analysts plainly believe Shattuck Labs is more favorable than Innate Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shattuck Labs 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.83Innate Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is STTK or IPHA more profitable? Innate Pharma's return on equity of 0.00% beat Shattuck Labs' return on equity.Company Net Margins Return on Equity Return on Assets Shattuck LabsN/A -79.69% -69.13% Innate Pharma N/A N/A N/A Which has more risk and volatility, STTK or IPHA? Shattuck Labs has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Which has stronger valuation & earnings, STTK or IPHA? Innate Pharma has higher revenue and earnings than Shattuck Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioShattuck Labs$4.61M8.42-$75.41M-$1.39-0.58Innate Pharma$12.62M14.02-$53.53MN/AN/A SummaryInnate Pharma beats Shattuck Labs on 7 of the 13 factors compared between the two stocks. Get Shattuck Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STTK vs. The Competition Export to ExcelMetricShattuck LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.76M$2.94B$5.54B$9.42BDividend YieldN/A2.48%3.76%4.04%P/E Ratio-0.5819.8828.2619.78Price / Sales8.42306.86415.2388.82Price / CashN/A41.8435.8558.18Price / Book0.487.678.115.65Net Income-$75.41M-$55.28M$3.25B$257.97M7 Day Performance-0.77%4.87%1.63%3.74%1 Month Performance-15.44%13.14%7.62%11.95%1 Year Performance-81.61%3.51%32.74%19.22% Shattuck Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STTKShattuck Labs3.6913 of 5 stars$0.81+8.6%$7.50+826.8%-81.6%$38.76M$4.61M-0.58100News CoverageIPHAInnate Pharma1.8724 of 5 stars$1.70-2.5%$11.00+547.1%-10.7%$156.71M$21.77M0.00220News CoverageLFVNLifevantage4.3065 of 5 stars$12.38+3.1%$30.50+146.4%+96.2%$155.86M$200.16M17.94260News CoverageIMRXImmuneering3.239 of 5 stars$4.17-5.7%$13.25+217.7%+272.1%$150.06MN/A-2.1360ENTAEnanta Pharmaceuticals3.4924 of 5 stars$6.96+6.1%$18.00+158.6%-47.3%$148.81M$67.64M-1.53160Positive NewsSPROSpero Therapeutics3.4432 of 5 stars$2.64-6.0%$5.00+89.4%+69.3%$147.60M$47.98M-2.06150LXEOLexeo Therapeutics1.6838 of 5 stars$4.44-0.7%$16.60+273.9%-62.9%$147.41M$650K-1.3558THTXTheratechnologiesN/A$3.15flatN/A+101.3%$144.84M$85.87M-16.58140GLSIGreenwich LifeSciences1.8556 of 5 stars$10.81-0.3%$39.00+260.8%-21.8%$144.53MN/A-8.583News CoverageHigh Trading VolumeRAPTRapt Therapeutics4.1739 of 5 stars$8.72+3.1%$19.80+127.1%-55.6%$144.23M$1.53M-0.4580IKTInhibikase Therapeutics1.2534 of 5 stars$1.94+4.9%$6.50+235.1%+22.7%$144.22MN/A-0.736 Related Companies and Tools Related Companies Innate Pharma Competitors Lifevantage Competitors Immuneering Competitors Enanta Pharmaceuticals Competitors Spero Therapeutics Competitors Lexeo Therapeutics Competitors Theratechnologies Competitors Greenwich LifeSciences Competitors Rapt Therapeutics Competitors Inhibikase Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STTK) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shattuck Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shattuck Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STTK Stock Alerts